Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL

Model scores of the 29,894 trials active now.

Model score 32% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiacancercellchronicsmall
  Phrases that lowered it: and safetyefficacy andkgweightsafety of
• Sponsor's past termination rate: 28.6% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 5.1% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 5 (raises risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 91 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) NCT01292135 · started 2011 · scored riskier than 72% of active trials completed
• Safety of PCI-32765 in Chronic Lymphocytic Leukemia NCT01105247 · started 2010 · scored riskier than 98% of active trials completed
• Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients NCT01520519 · started 2012 · scored riskier than 97% of active trials completed
• Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia NCT01109069 · started 2010 · scored riskier than 99% of active trials completed
• Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma NCT00849654 · started 2009 · scored riskier than 81% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.